Pearlman, Alexander H. http://orcid.org/0000-0002-3504-7517
Hwang, Michael S.
Konig, Maximilian F. http://orcid.org/0000-0001-5045-5255
Hsiue, Emily Han-Chung
Douglass, Jacqueline
DiNapoli, Sarah R.
Mog, Brian J. http://orcid.org/0000-0001-9988-7147
Bettegowda, Chetan
Pardoll, Drew M.
Gabelli, Sandra B.
Papadopoulos, Nicholas http://orcid.org/0000-0001-7135-7451
Kinzler, Kenneth W.
Vogelstein, Bert
Zhou, Shibin http://orcid.org/0000-0003-1941-4425
Article History
Received: 22 August 2020
Accepted: 13 April 2021
First Online: 17 May 2021
Change Date: 29 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-021-00246-0
Competing interests
: The Johns Hopkins University has filed patent applications related to technologies described in this paper, on which A.H.P., M.S.H., E.H.-C.H., J.D., B.J.M., N.P., K.W.K., B.V., D.M.P. and S.Z. are listed as inventors: HLA-restricted epitopes encoded by somatically mutated genes (15/560,241, USPTO; 2016235251, European Patent Office); MANAbodies and Methods of Using (16/614,005, USPTO; 18802867.4, European Patent Office); MANAbodies Targeting Tumor Antigens and Methods of Using (63/059,638, USPTO; PCT/US2020/065617, World IP Organization). These applications include methods for identifying public neoantigens and the development of therapeutic agents that target these neoantigens. B.V., K.W.K. and N.P. are founders of Thrive Earlier Detection. K.W.K. and N.P. are consultants to Thrive Earlier Detection and were on its Board of Directors. B.V., K.W.K., N.P. and S.Z. own equity in Exact Sciences. B.V., K.W.K., N.P., S.Z. and D.M.P. are founders of, and serve or may serve as consultants to, ManaT Bio, and hold or may hold equity in ManaT Holdings, LLC. B.V., K.W.K., N.P. and S.Z. are founders of, hold equity in and serve as consultants to Personal Genome Diagnostics. S.Z. has a research agreement with BioMed Valley Discoveries. S.B.G. is a founder of and holds equity in AMS. K.W.K. and B.V. are consultants to Sysmex, Eisai and Cage Pharma and hold equity in Cage Pharma. B.V. is also a consultant to Catalio. K.W.K., B.V., S.Z. and N.P. are consultants to and hold equity in NeoPhore. N.P. is an advisor to and holds equity in Cage Pharma. C.B. is a consultant to DePuy Synthes and Bionaut Labs. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K., S.Z., N.P. and C.B. are inventors on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies. M.F.K. received personal fees from Bristol Myers Squibb and Celltrion. D.M.P. reports grant and patent royalties through his institution from Bristol Myers Squibb, a grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals and founder equity from Potenza; is a consultant for Aduro Biotech, Amgen, AstraZeneca (MedImmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona and Immunomic Therapeutics; is on the scientific advisory board of Five Prime Therapeutics, Catalio and WindMIL; and is on the board of directors for Dracen Pharmaceuticals.